Endocrine Testing Market Report by Test Type (Thyroid Test, Insulin Test, Human Chorionic Gonadotropin Test, Prolactin Test, Luteinizing Hormone Test, Progesterone Test, and Others), Technology (Immunoassay, Tandem Mass Spectroscopy, Sensor Technology, LC
Endocrine Testing Market Report by Test Type (Thyroid Test, Insulin Test, Human Chorionic Gonadotropin Test, Prolactin Test, Luteinizing Hormone Test, Progesterone Test, and Others), Technology (Immunoassay, Tandem Mass Spectroscopy, Sensor Technology, LC-MS, and Others), End Use (Hospitals, Ambulatory Care Centers, Clinical Laboratories, and Others), and Region 2024-2032
The global endocrine testing market size reached US$ 11.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.8% during 2024-2032.
Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders. The testing aids in detecting an imbalance in the concentrations of hormones that may lead to the development of certain chronic conditions. These disorders are usually tested by fine-needle aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI) and venous sampling. The test results thus obtained can assist in determining the progression of the disorder and monitoring the effects of the treatment being provided to the patient.
The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing’s disease, gigantism, hypothyroidism and hyperthyroidism, represents one of the key factors driving the growth of the market. Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth. Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients. In line with this, the rising geriatric population is acting as another major growth-inducing factor. Moreover, due to the onset of the coronavirus (COVID-19) pandemic, endocrine testing is being widely used to detect hyperglycemia in infected patients. Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market. Healthcare centers, laboratories and diagnostic centers are also using technologically advanced liquid chromatography with mass spectrometry (LC-MS) techniques to provide highly precise and accurate results. Other factors, including improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global endocrine testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type, technology, and end use.
Breakup by Test Type:
Thyroid Test
nsulin Test
Human Chorionic Gonadotropin Test
Prolactin Test
Luteinizing Hormone Test
Progesterone Test
Others
Breakup by Technology:
mmunoassay
Tandem Mass Spectroscopy
Sensor Technology
LC-MS
Others
Breakup by End Use:
Hospitals
Ambulatory Care Centers
Clinical Laboratories
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., BioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche AG (Roche Holding AG), Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens Aktiengesellschaft) and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
How has the global endocrine testing market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global endocrine testing market?
What are the key regional markets?
What is the breakup of the market based on the test type?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the end use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global endocrine testing market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Endocrine Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Test Type
6.1 Thyroid Test
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Insulin Test
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Human Chorionic Gonadotropin Test
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Prolactin Test
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Luteinizing Hormone Test
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Progesterone Test
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Technology
7.1 Immunoassay
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Tandem Mass Spectroscopy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Sensor Technology
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 LC-MS
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by End Use
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Ambulatory Care Centers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Clinical Laboratories
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Agilent Technologies Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Bio-Rad Laboratories Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 BioMerieux SA
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 DiaSorin S.p.A.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 SWOT Analysis
14.3.7 Laboratory Corporation of America Holdings
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Quest Diagnostics Incorporated
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Siemens Healthineers AG (Siemens Aktiengesellschaft)